ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 54 filers reported holding ALPINE IMMUNE SCIENCES INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,672 | -92.7% | 670 | -93.5% | 0.00% | – |
| Q2 2023 | $105,637 | +2516.1% | 10,276 | +1864.8% | 0.00% | – |
| Q1 2023 | $4,038 | -7.5% | 523 | -12.0% | 0.00% | – |
| Q4 2022 | $4,366 | +9.2% | 594 | -4.0% | 0.00% | – |
| Q3 2022 | $4,000 | -71.4% | 619 | -61.2% | 0.00% | – |
| Q2 2022 | $14,000 | +55.6% | 1,597 | +53.1% | 0.00% | – |
| Q1 2022 | $9,000 | -82.7% | 1,043 | -72.3% | 0.00% | – |
| Q4 2021 | $52,000 | +271.4% | 3,766 | +184.0% | 0.00% | – |
| Q3 2021 | $14,000 | +180.0% | 1,326 | +140.2% | 0.00% | – |
| Q2 2021 | $5,000 | -92.1% | 552 | -90.7% | 0.00% | – |
| Q1 2021 | $63,000 | -43.8% | 5,916 | -33.5% | 0.00% | – |
| Q4 2020 | $112,000 | – | 8,896 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $76,809,898 | 25.63% |
| Lynx1 Capital Management LP | 2,404,614 | $27,532,830 | 18.21% |
| GREAT POINT PARTNERS LLC | 3,078,633 | $35,250,348 | 6.42% |
| Ghost Tree Capital, LLC | 664,132 | $7,604,311 | 2.50% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $34,186,918 | 2.27% |
| Paradigm Biocapital Advisors LP | 2,421,743 | $27,728,957 | 1.88% |
| COMMODORE CAPITAL LP | 1,325,000 | $15,171,250 | 1.77% |
| Nan Fung Group Holdings Ltd | 182,280 | $2,087,106 | 1.69% |
| Omega Fund Management, LLC | 153,700 | $1,759,865 | 1.62% |
| Octagon Capital Advisors LP | 750,000 | $8,587,500 | 1.32% |